BG
AVLN

Bellevue Group’s Avalyn Pharma AVLN Stock Holding History

Bellevue Group’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4M Buy
+1,350,000
New +$39M 0.94% 31

Other funds holding AVLN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bellevue Group's AVLN Position: Q2 2026 in Review

Bellevue Group opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 1,350,000 shares worth $44.4M. The stake represents 0.94% of the portfolio and ranks #31 among its holdings.

77 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • Bellevue Group held 1,350,000 shares of Avalyn Pharma worth $44.4M as of Q2 2026.
  • Avalyn Pharma was a new Bellevue Group position in Q2 2026.
  • Avalyn Pharma made up 0.94% of Bellevue Group's portfolio in Q2 2026, its #31 holding.
  • 77 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.